全文获取类型
收费全文 | 6075篇 |
免费 | 444篇 |
国内免费 | 57篇 |
专业分类
耳鼻咽喉 | 26篇 |
儿科学 | 133篇 |
妇产科学 | 114篇 |
基础医学 | 943篇 |
口腔科学 | 103篇 |
临床医学 | 580篇 |
内科学 | 1575篇 |
皮肤病学 | 103篇 |
神经病学 | 733篇 |
特种医学 | 157篇 |
外科学 | 504篇 |
综合类 | 14篇 |
一般理论 | 1篇 |
预防医学 | 386篇 |
眼科学 | 65篇 |
药学 | 489篇 |
中国医学 | 13篇 |
肿瘤学 | 637篇 |
出版年
2024年 | 6篇 |
2023年 | 66篇 |
2022年 | 158篇 |
2021年 | 268篇 |
2020年 | 132篇 |
2019年 | 166篇 |
2018年 | 232篇 |
2017年 | 166篇 |
2016年 | 187篇 |
2015年 | 245篇 |
2014年 | 276篇 |
2013年 | 317篇 |
2012年 | 533篇 |
2011年 | 547篇 |
2010年 | 273篇 |
2009年 | 242篇 |
2008年 | 429篇 |
2007年 | 446篇 |
2006年 | 385篇 |
2005年 | 382篇 |
2004年 | 323篇 |
2003年 | 327篇 |
2002年 | 245篇 |
2001年 | 33篇 |
2000年 | 13篇 |
1999年 | 18篇 |
1998年 | 30篇 |
1997年 | 25篇 |
1996年 | 23篇 |
1995年 | 15篇 |
1994年 | 15篇 |
1993年 | 12篇 |
1992年 | 7篇 |
1991年 | 10篇 |
1990年 | 5篇 |
1989年 | 3篇 |
1988年 | 4篇 |
1986年 | 1篇 |
1985年 | 1篇 |
1984年 | 1篇 |
1983年 | 1篇 |
1982年 | 1篇 |
1980年 | 1篇 |
1979年 | 1篇 |
1971年 | 1篇 |
1970年 | 1篇 |
1969年 | 2篇 |
1918年 | 1篇 |
排序方式: 共有6576条查询结果,搜索用时 15 毫秒
61.
Cesare Greco Piero A. Chiavari Giuseppe Campolongo Simona Mariani Fortunato Messa Demetrio Tallarico Michele Schiariti Carlo Gonnella Carlo Gaudio 《Catheterization and cardiovascular interventions》2008,72(4):538-541
Objectives : To reduce risks, discomfort, cost, and operative time for percutaneous patent foramen ovale (PFO) closure, we propose to perform this procedure under transesophageal echo‐guidance using a 10 Fr. catheter introduced through nasal way (TEENW). Background : Transesophageal or intracardiac echocardiography is commonly used to guide percutaneous PFO closure. Sedation needed quite frequently during transesophageal echocardiography, increased patients' discomfort, procedure prolongation, costs, use of both femoral veins, and additional intracardiac manipulations are the main limitations of standard techniques. Methods : We enrolled 20 consecutive patients with a history of cerebral ischemia and PFO with right‐to‐left shunt. In 15 patients Amplatzer® PFO occluder was used, whereas in five patients with longer PFO tunnel (>10 mm) Cardia Intrasept® was selected. Without sedation, a multifrequency monoplane probe, developed for intracardiac echocardiography, was introduced into the nostril and advanced forward the esophagus. Then under echo guidance, the closing device was presented, opened and released. Results : Procedure lasted for an average of 33.3 min, and no complications were seen. At procedure's completion, six patients showed persistence of reduced shunt during Valsalva manoeuvre. At six‐month follow‐up, shunts disappeared in all patients. Conclusion : TEENW is safe and well tolerated, and images' quality is high enough to deserve widespread adoption of this technique for PFO closure. © 2008 Wiley‐Liss, Inc. 相似文献
62.
Marjolein H Kamphuis Sandra Kalmijn Marja A R Tijhuis Mirjam I Geerlings Simona Giampaoli Aulikki Nissinen Diederick E Grobbee Daan Kromhout 《European journal of cardiovascular prevention and rehabilitation》2006,13(2):199-206
BACKGROUND: Depressive symptoms have been suggested to increase the risk of cardiovascular diseases, but this may reflect reversed causality. We investigated to what extent depressive symptoms are a true risk factor for cardiovascular mortality in elderly men. DESIGN: The Finland, Italy and Netherlands Elderly (FINE) study is a prospective cohort study conducted in Finland, Italy and The Netherlands. METHODS: Depressive symptoms were measured with the Zung self-rating Depression Scale in 799 elderly men, aged 70-90 years, free from cardiovascular diseases. Using Cox models, hazard ratios (HRs) were calculated for specific cardiovascular mortality endpoints. The analyses were adjusted for potential confounders, stratified on country and repeated after exclusion of men who died from cardiovascular diseases up to 5 years after baseline. RESULTS: During 10-years of follow-up 224 (28%) men died from cardiovascular diseases. The adjusted hazard for a five-point increase in depressive symptoms was 1.15 [95% confidence interval (CI) 1.08-1.23] for cardiovascular mortality. This risk was stronger for mortality from stroke (HR 1.35; 95% CI 1.19-1.53) and heart failure (HR 1.16; 95% CI 1.00-1.35) in comparison with mortality from coronary heart disease (HR 1.08; 95% CI 0.97-1.20) and other degenerative heart diseases (HR 1.06; 95% CI 0.91-1.23). Exclusion of men who died from cardiovascular diseases within 5 years after baseline did not change the strength of the associations. There were no significant differences in HRs between northern and southern Europe. CONCLUSIONS: This study provides further and more convincing prospective evidence for depressive symptoms as a risk factor for cardiovascular mortality in elderly men. 相似文献
63.
Paolo Ortolani Antonio Marzocchi Cinzia Marrozzini Tullio Palmerini Francesco Saia Carlo Serantoni Matteo Aquilina Simona Silenzi Federica Baldazzi Daniele Grosseto Nevio Taglieri Robin M T Cooke Maria Letizia Bacchi-Reggiani Angelo Branzi 《European heart journal》2006,27(13):1550-1557
AIMS: Treatment delay is a powerful predictor of survival in ST-elevation myocardial infarction (STEMI) patients undergoing primary percutaneous coronary intervention (PCI). We investigated effectiveness of pre-hospital diagnosis of STEMI with direct referral to PCI, alongside more conventional referral strategies. METHODS AND RESULTS: From January 2003 to December 2004, 658 STEMI patients were referred for primary PCI at our intervention laboratory. Three predefined referral routes were compared: (1) for patients within 90 min drive of the PCI centre, pre-hospital diagnosis and direct transportation (n=166), (2) diagnosis at the interventional hospital emergency department (n=316), (3) diagnosis at local hospitals before transportation (n = 176). Pre-hospital diagnosis was associated with more than 45 min reduction in treatment delay (P = 0.001). No significant difference in in-hospital mortality was apparent in the overall study population. In the cardiogenic shock subgroup (n = 80), pre-hospital diagnosis was associated with a two-thirds reduction in in-hospital mortality (P = 0.019); mortality was only 6.2% in shock patients who underwent PCI in < 2 h. CONCLUSION: This study shows that pre-hospital diagnosis can provide a reduction in primary PCI treatment delay, and suggests the hypothesis that this referral strategy might provide survival benefits to patients with cardiogenic shock. 相似文献
64.
Paola Frati Chrystalla Kyriakou Alessandro Del Rio Enrico Marinelli Gianluca Montanari Vergallo Simona Zaami Francesco P. Busardò 《Current Neuropharmacology》2015,13(1):5-11
Cognitive enhancement can be defined as the use of drugs and/or other means with the
aim to improve the cognitive functions of healthy subjects in particular memory, attention, creativity
and intelligence in the absence of any medical indication. Currently, it represents one of the most
debated topics in the neuroscience community. Human beings always wanted to use substances to
improve their cognitive functions, from the use of hallucinogens in ancient civilizations in an attempt
to allow them to better communicate with their gods, to the widespread use of caffeine under various
forms (energy drinks, tablets, etc.), to the more recent development of drugs such as stimulants and glutamate activators.
In the last ten years, increasing attention has been given to the use of cognitive enhancers, but up to now there is still only
a limited amount of information concerning the use, effect and functioning of cognitive enhancement in daily life on
healthy subjects. The first aim of this paper was to review current trends in the misuse of smart drugs (also known as
Nootropics) presently available on the market focusing in detail on methylphenidate, trying to evaluate the potential risk
in healthy individuals, especially teenagers and young adults. Moreover, the authors have explored the issue of cognitive
enhancement compared to the use of Anabolic Androgenic Steroids (AAS) in sports. Finally, a brief overview of the
ethical considerations surrounding human enhancement has been examined. 相似文献
65.
66.
67.
Lars Bendtsen Simona Sacco Messoud Ashina Dimos Mitsikostas Fayyaz Ahmed Patricia Pozo-Rosich Paolo Martelletti 《The journal of headache and pain》2018,19(1):91
OnabotulinumtoxinA is being increasingly used in the management of chronic migraine (CM). Treatment with onabotulinumtoxinA poses challenges compared with traditional therapy with orally administered preventatives. The European Headache Federation identified an expert group that was asked to develop the present guideline to provide recommendations for the use of onabotulinumtoxinA in CM. The expert group recommend onabotulinumtoxinA as an effective and well-tolerated treatment of CM. Patients should preferably have tried two to three other migraine prophylactics before start of onabotulinumtoxinA. Patients with medication overuse should be withdrawn from the overused medication before initiation of onabotulinumtoxinA if feasible, if not onabotulinumtoxinA can be initiated from the start or before withdrawal. OnabotulinumtoxinA should be administered according to the PREEMPT injection protocol, i.e. injecting 155 U–195 U to 31–39 sites every 12-weeks. We recommend that patients are defined as non-responders, if they have less than 30% reduction in headache days per month during treatment with onabotulinumtoxinA. However other factors such as headache intensity, disability and patient preferences should also be considered when evaluating response. Treatment should be stopped, if the patient does not respond to the first two to three treatment cycles. Response to continued treatment with onabotulinumtoxinA should be evaluated by comparing the 4 weeks before with the 4 weeks after each treatment cycle. It is recommended that treatment is stopped in patients with a reduction to less than 10 headache days per month for 3 months and that patients are re-evaluated 4–5 months after stopping onabotulinumtoxinA to make sure that the patient has not returned to CM. Questions regarding efficacy and tolerability of onabotulinumtoxinA could be answered on the basis of scientific evidence. The other recommendations were mainly based on expert opinion. Future research on the treatment of CM with onabotulinumtoxinA may further improve the management of this highly disabling disorder. 相似文献
68.
Antonello D’Andrea Juri Radmilovic Stefano Caselli Andreina Carbone Raffaella Scarafile Simona Sperlongano Giampaolo Tocci Tiziana Formisano Francesca Martone Biagio Liccardo Michele D’Alto Eduardo Bossone Maurizio Galderisi Paolo Golino 《The international journal of cardiovascular imaging》2018,34(10):1561-1561
69.
70.
Mura Eleonora Masnada Silvia Antonello Clara Parazzini Cecilia Izzo Giana Garau Jessica Sproviero Daisy Cereda Cristina Orcesi Simona Veggiotti Pierangelo Zuccotti Gianvincenzo Dilillo Dario Penagini Francesca Tonduti Davide 《Metabolic brain disease》2021,36(5):859-863
Metabolic Brain Disease - Aicardi-Goutières Syndrome (AGS) is a monogenic leukodystrophy with pediatric onset, clinically characterized by a variable degree of neurologic impairment. It... 相似文献